Sign inJoin waitlistJoin the waitlist

DP

Doris Ponce

Co-Chair, Center for Hematologic Malignancies Translational Research Council · New York Presbyterian Hospital

Credentials: · · · · · · ·

History

Center for Hematologic Malignancies Translational Research Council Department · New York Presbyterian Hospital
Present
Graft-Versus-Host Disease Program · New York Presbyterian Hospital
Present
Center for Hematologic Malignancies Translational Research Council Department · Memorial Sloan Kettering Cancer Center
Present

Hematology and Medical Oncology
New York Medical College
2003–2006
Memorial Sloan Kettering Cancer Center
2002–2003
Albert Einstein College of Medicine of Yeshiva University
1999–2002
Clinical and Translational Cancer Research, The Gerstner Sloan Kettering Graduate School of Biomedical Sciences
Central University of Venezuela
1995–1999

Research

The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
Blood · 2014 · 722 citations
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
New England Journal of Medicine · 2020 · 618 citations
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation · 2015 · 615 citations

MP
Miguel-Angel Perales
70 papers
SG
Sergio Giralt
69 papers
Juliet Barker
51 papers
AJ
Ann Jakubowski
43 papers
EP
Esperanza Papadopoulos
41 papers
RT
Roni Tamari
32 papers
Craig Sauter
31 papers
PD
Parastoo Dahi
31 papers
Boglarka Gyurkocza
28 papers
Marcel van den Brink
26 papers
BS
Brian Shaffer
25 papers
Christina Cho
25 papers · 4 as a fellow

Grants

Microbiome Manipulation Through Oral Live Biotherapeutic Product (LBP) for the Treatment of Gut Acute Graft-Versus-Host Disease (GVHD)
National Heart, Lung, and Blood Institute · R34
Contact PI · $281.7K · Sloan-Kettering Inst Can Research
2026–2029
Intestinal Microbiome Restoration in Allogeneic Stem Cell Transplantation
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.8M · Sloan-Kettering Inst Can Research
2023–2028

Clinical trials

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2026–2029
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2025–2029
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
Principal investigator · Completed · Phase 1
Seres Therapeutics, Inc.
2021–2024
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2017–2021